Orga F, Mitchell A, Freixes M, Aletta F, Alsina-Pages RM, Foraster M. Multilevel annoyance modelling of short environmental sound recordings. Sustainability. 2021 May 21;13(11):5779. doi: 10.3390/su13115779
DiSantostefano RL, Sutphin J, Hedrick JA, Klein K, Mansfield C. Parent preferences for delaying insulin dependence in children at risk of Stage III Type 1 Diabetes. Diabetes Technol Ther. 2020 Mar 11. doi: 10.1089/dia.2019.0444.
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Park EM, Tan X, Stephenson EM, Deal AM, Yopp JM, Rosenstein DL, Edwards T, Song MK. Psychometric analysis of the parenting concerns questionnaire in women with metastatic cancer. J Pain Symptom Manage. 2018 Feb;55(2):451-7. doi: 10.1016/j.jpainsymman.2017.09.021
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Gabbay RA, McGinley (Miller) EL. Editorial - The Affordable Care Act, technology, and type 1 diabetes mellitus. Diabetes Technol Ther. 2014 Dec;16(12):819-21. doi: 10.1089/dia.2014.0258
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Chirila C, Earnshaw SR, Black L, McDade CL, Roskell NS, Shannon PR, Montorsi F, Andriole GL. Economic analysis: randomized, placebo-controlled clinical trial of dutasteride in men at high risk for prostate cancer. J Cancer Sci Ther. 2011;S3(004). doi: 10.4172/1948-5956.S3-004
Williams VSL, Smith M, Fehnel SE. The validity and utility of the BPI interference measures for evaluating the impact of osteoarthritic pain. J Pain Symptom Manage. 2006 Jan 1;31(1):48-57.
Neighbors DM, Bell TJ, Wilson J, Dodd SL. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage. 2001 Feb 1;21(2):129-43. doi: 10.1016/s0885-3924(00)00247-5.
Neighbors DM, Dodd SL. Re: economic evaluation of fentanyl - Response. J Pain Symptom Manage. 2001 Jan 1;22(1):541-3.